News

The Intellectual Property Office (IPO) is seeking feedback on levels of awareness of the Lambert Toolkit, how it is being used and its impact amongst businesses and universities. The Lambert toolkit helps academic institutions and industrial partners carry out collaborative research projects. 

As part of my role in BBSRC, I work at the interface between funding research and helping universities to realise their impact from these investments. In recent years, I have seen a resurgence of the use of metrics to measure the outputs of research. As more money is being committed to research and knowledge exchange, we are increasingly being asked what difference this is making to the economy and society. This is a good thing, as everyone should be accountable for what they do. However, how should we measure this, and how do we ensure our measures are appropriate for all situations and sectors?

The Biotechnology and Biological Sciences Research Council (BBSRC) part of UK Research and Innovation, is currently seeking proposals to the Royal Society of Edinburgh (RSE) Enterprise Fellowship programme which supports researchers who wish to play a key role in the commercialisation of their research.

The Science and Technology Facilities Council supports innovation opportunities arising from its research portfolio through the commercialisation of technologies, industrial use of the National Laboratories and the creation of innovation eco-systems on the National Science and Innovation Campuses at Sci-Tech Daresbury and Harwell. Strategic advice on the range of activities to deliver on the innovation goals set out in the Strategic Delivery Plan is provided by the Innovation Board which reports to STFC Council.

Research England has today published a document detailing proposals for how the Knowledge Exchange Framework (KEF) could work and would like to hear the HE sector’s views on these proposals.

This Quarter's edition of Spinouts UK looks at the ways in which universities can make the most of their environment with spotlights on Swansea University and the Midlands MIRA initiative.

PraxisAuril member the Institute for Cancer Research has released a report looking at cancer drug delivery in the NHS and the rate of drug development across different types of cancer. ‘Patent to Patient’ analysed the regulatory regime and found that NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use.